   Elizabeth Hougen | Isis Pharmaceuticals , Inc. | ZoomInfo.com





Elizabeth L. Hougen - Ionis Pharmaceuticals



























































































Elizabeth L. Hougen




Senior Vice President, Finance and Chief Financial Officer
Ms. Hougen is Senior Vice President of Finance and Chief Financial Officer of Ionis Pharmaceuticals. She is responsible for overseeing the operations of finance, accounting, information technology, facilities, and purchasing. Ms. Hougen joined Ionis in May 2000.
Prior to joining Ionis, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
Ms. Hougen received her M.B.A. at the University of San Diego, San Diego, California and her B.A. from Franklin and Marshall College, Lancaster, Pennsylvania.






















About

Mission & Values
In The Community
Management
Board of Directors
Contact


Patients

Patient Resources
Clinical Trials

Drug Approval Process
Learn More About Ionis’ Clinical Trials




Pipeline
R&D

Antisense Technology

Discovery Platform
Basic Science
Antisense Drugs
Medicinal Chemistry
Antisense Approaches


Intellectual Property
Strategic Alliances

Pharmaceutical Partners
Satellite Companies




Investors & Media

News & Events

Press Releases
Archived Webcasts
Event Calendar


Corporate Governance

Board of Directors
Board Criteria
Director Compensation and Board Meeting Attendance
Committee Composition
Certificates of Incorporation
Bylaws
Code of Ethics
Clawback Policy
RSU Holding Guidelines
Annual Meeting


Stock Information

Stock Quote
Stock Chart
Analyst Coverage
Ownership Profile


Financials

Annual Reports
SEC Filings


Shareholder Services

Investor FAQ
Information Request


Press Kit


Careers

Available Positions

Search Open Jobs
Browse Open Jobs
Edit Your Profile
View Submitted Applications


Culture & Values
Benefits
Equal Opportunity
Intern Program
Post-Doctoral Program











Elizabeth L. Hougen - Ionis Pharmaceuticals



























































































Elizabeth L. Hougen




Senior Vice President, Finance and Chief Financial Officer
Ms. Hougen is Senior Vice President of Finance and Chief Financial Officer of Ionis Pharmaceuticals. She is responsible for overseeing the operations of finance, accounting, information technology, facilities, and purchasing. Ms. Hougen joined Ionis in May 2000.
Prior to joining Ionis, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
Ms. Hougen received her M.B.A. at the University of San Diego, San Diego, California and her B.A. from Franklin and Marshall College, Lancaster, Pennsylvania.






















About

Mission & Values
In The Community
Management
Board of Directors
Contact


Patients

Patient Resources
Clinical Trials

Drug Approval Process
Learn More About Ionis’ Clinical Trials




Pipeline
R&D

Antisense Technology

Discovery Platform
Basic Science
Antisense Drugs
Medicinal Chemistry
Antisense Approaches


Intellectual Property
Strategic Alliances

Pharmaceutical Partners
Satellite Companies




Investors & Media

News & Events

Press Releases
Archived Webcasts
Event Calendar


Corporate Governance

Board of Directors
Board Criteria
Director Compensation and Board Meeting Attendance
Committee Composition
Certificates of Incorporation
Bylaws
Code of Ethics
Clawback Policy
RSU Holding Guidelines
Annual Meeting


Stock Information

Stock Quote
Stock Chart
Analyst Coverage
Ownership Profile


Financials

Annual Reports
SEC Filings


Shareholder Services

Investor FAQ
Information Request


Press Kit


Careers

Available Positions

Search Open Jobs
Browse Open Jobs
Edit Your Profile
View Submitted Applications


Culture & Values
Benefits
Equal Opportunity
Intern Program
Post-Doctoral Program








Elizabeth L Hougen - San Diego, CA | Intelius



























Sign In



We found Elizabeth L Hougen in San Diego, CA


Elizabeth L Hougen

                                                                                       Intelius found that Elizabeth L Hougen  is  a female between 50 and 60 years old from San Diego, CA.  We have connected them to
                11 addresses,
                7 phones,
                and 3 relatives or associates.
         





Also Known As

Elizabeth L Schrader


Get Report Now

Age

Elizabeth L Hougen is in her 50s

Elizabeth Has Lived In

San Diego, CA
Carlsbad, CA
New York, NY

Elizabeth's Relatives

Murray Hougen
Schrader Hougen
Erik Hougen







Elizabeth L Hougen



Zodiac SignGemini



GenderFemale



Professional Status
Chief Financial Officer at Isis Pharmaceuticals , Inc.



Get Report Now










Want to know more about Elizabeth? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Elizabeth, or use our people search engine to find others.
Get Background Check on Elizabeth L Hougen
Get a Criminal Check on Elizabeth L Hougen
Get a Public Record Report on Elizabeth L Hougen
Get a People Search Report on Elizabeth L Hougen


Elizabeth L Hougen's Contact Information
Known Cities Lived In
Find out where Elizabeth L Hougen has lived as well as Elizabeth L Hougen's phone numbers and email addresses.




Elizabeth L Hougen Has Lived in 2 States
California Address for Elizabeth L Hougen


11215 A********* C* 

San Diego, CA


Has Lived In

San Diego, CA
Carlsbad, CA


Get Full Address Report










Phone Numbers Associated with Elizabeth L Hougen

(858) ***-**** - San Diego, CA 
(760) ***-****
(858) ***-**** - San Diego, CA 


Get Full Phone Report



Email Addresses Associated with Elizabeth L Hougen

b*****n@***.com


Get Email Report




Elizabeth L Hougen's Education Information
Known Schools Attended
Learn about Elizabeth L Hougen's academic history.  Find out which schools Elizabeth L Hougen attended, the dates attended as well as the degrees Elizabeth L Hougen received.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Elizabeth L Hougen Has Attended 1 School
San Diego State University-California State University 


Elizabeth L Hougen's Professional Information
Information regarding Elizabeth L Hougen's professional history.  Find out previous places Elizabeth L Hougen has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Elizabeth L Hougen Has Worked at 8 Places
Company: Isis Pharmaceuticals , Inc.
               Title: Chief Financial Officer
Company: Isis Pharmaceuticals , Inc.
               Title: Senior Vice President, Finance and Chief Financial Officer
Elizabeth L Hougen's Experience
Title: Chief Financial Officer
               Company: Isis Pharmaceuticals , Inc.
Job Details
               Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH. Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe. Isis' patents provide strong and extensive protection for its drugs and technology.
Title: Senior Vice President, Finance and Chief Financial Officer
               Company: Isis Pharmaceuticals , Inc.
Job Details
               Isis Pharmaceuticals, Inc. (Isis) is engaged in antisense technology, exploiting a drug discovery platform to create a pipeline of drugs. The Company operates in a two principal segments: Drug Discovery and Development and Regulus Therapeutics Inc. Within the Drug Discovery and Development segment, its drug discovery platform enables the Company to identify drugs, providing potential targets to treat a range of diseases. As of December 31, 2008, the Company has 19 drugs in development. Its partners are licensed to develop, with the Company’s support, 15 of these 19 drugs. The Company and Alnylam established Regulus Therapeutics Inc. as a company focused on the discovery, development and commercialization of microRNA therapeutics. In January 2009, the Company sold its subsidiary, Ibis Biosciences, Inc. to Abbott Molecular Inc. (AMI), a wholly owned subsidiary of Abbott Laboratories.(Source: 10-K)
Additional Professional Information on Elizabeth L Hougen

 See Elizabeth L Hougen's LinkedIn Profile



Elizabeth L Hougen's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Elizabeth L Hougen


Elizabeth L Hougen's known Social Networks And Potential Email Matches

Find all of Elizabeth L Hougen's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Elizabeth Hougen
Username Matches

                  ElizabethHougen
                  HougenElizabeth
                  Elizabeth.Hougen
                  Hougen.Elizabeth
                  Elizabeth_Hougen
                  Hougen_Elizabeth
                  Elizabeth-Hougen
                  Hougen-Elizabeth
                  EHougen
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
E Hougen







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.




















Elizabeth L. Hougen - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Elizabeth L. Hougen
Senior Vice President, Finance and Chief Financial Officer at Ionis Pharmaceuticals, Inc.


View Full Profile
Are you Elizabeth L. Hougen? Claim your profile


 


Sign up for Equilar Atlas and view Elizabeth L. Hougen's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Elizabeth L. Hougen's  network and community.
												FOLLOW changes in Elizabeth L. Hougen's employment and money-in-motion.
												CONNECT with Elizabeth L. Hougen through your network of contacts.
												








Elizabeth L. Hougen's Executive Work History


Current


Senior Vice President, Finance and Chief Financial Officer, 
Ionis Pharmaceuticals, Inc.


Past
To view Elizabeth L. Hougen's complete executive work history, sign up now
Age
55

 
 


Elizabeth L. Hougen's Biography




			Ms. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012, Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as our Vice President, Finance. Prior to joining Ionis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
		
Source: Ionis Pharmaceuticals, Inc. on 03/01/2017
		
	

 






Sign up for Equilar Atlas and view Elizabeth L. Hougen's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Elizabeth L. Hougen. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Elizabeth L. Hougen's  network and community.
												FOLLOW changes in Elizabeth L. Hougen's employment and money-in-motion.
												CONNECT with Elizabeth L. Hougen through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Elizabeth L. Hougen


















Elizabeth L. Hougen's Connections (14)





Sign up now to view Elizabeth L. Hougen's 14 connections »









Frederick T. Muto
Board Member, Ionis Pharmaceuticals, Inc.









Breaux B. Castleman
Board Member, Ionis Pharmaceuticals, Inc.









Richard S. Geary
Senior Vice President, Development, Ionis Pharmaceuticals, Inc.









Stanley T. Crooke
Chairman of the Board, President and Chief Executive Officer, Ionis Pharmaceuticals, Inc.









Sarah Boyce
Chief Business Officer, Ionis Pharmaceuticals, Inc.









B. Lynne Parshall
Dir. and Chief Operating Officer, Ionis Pharmaceuticals, Inc.









Joseph H. Wender
Board Member, Ionis Pharmaceuticals, Inc.









Spencer R. Berthelsen
Board Member, Ionis Pharmaceuticals, Inc.









C. Frank Bennett
Senior Vice President, Antisense Research, Ionis Pharmaceuticals, Inc.









Patrick R. O'Neil
Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary, Ionis Pharmaceuticals, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Elon R. Musk
CEO and Chairman, Tesla









Daniel A. DeMatteo
Executive Chairman, GameStop Corp.









David J. O'Connor
President and CEO, The Madison Square Garden Company












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

� 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
























 




 

Elizabeth L. Hougen's involvement in venture capital (via Isis Pharmaceuticals Inc)































Want to see more?Want to find out who got funded, and who’s funding the next big thing? in real time? all across the world? tailored to your specific areas of focus?100+ deals per dayGet access to the most exhaustive worldwide funding watch on the web!Comprehensive funding informationKnow about who invested in a company, which sites covered the event, the funding history, etc.Exclusive insightsView original analytics such as most dynamic industries, most active investors, and more!Stay aware!Get emailed when deals critical to your business happen. Filter by region, industry and topics of interest.As seen onHave a login?Sign inRegister now!It's free!Use your social accountOr fill in the quick form:Register nowpromise we won't spamSign invia your social account:via your existing WGF account:Remember meRegister, it's freeForgot your password?SIGN INForgot your password?Enter your e-mail and we will send you your new password.reset passwordThe world's largest funding base/people/191458-l-hougen-elizabethsection=people&subsection=detail&id=191458




			Search deals by company name, industry, location, investors...			
			




SEARCH


ElizabethL. HougenGet alertedif Elizabeth L. Hougen gets funded!Elizabeth L. HougenIsis Pharmaceuticals Inc - Senior Vice President, Finance and Chief Financial OfficerDeals involving Elizabeth L. Hougen$18,000,000 raised with Isis Pharmaceuticals Inc on October, 2014$3,000,000 raised with Isis Pharmaceuticals Inc on November, 2013$100,000,000 raised with Isis Pharmaceuticals Inc on September, 2013$31,000,000 raised with Isis Pharmaceuticals Inc on December, 2012$201,250,000 raised with Isis Pharmaceuticals Inc on August, 2012Please note that all data is automatically extracted and errors can occur.The WhoGotFunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and complete.Some of the profile information was collected using the Crunchbase API. For more details on the profile, please check Elizabeth L. Hougen on Crunchbase.Inaccurate Data? Help us improve WhoGotFunded: post a comment!


IONS Elizabeth L. Hougen Insider Trades for Ionis Pharmaceuticals Inc.


































Bulletin






Investor Alert







Tokyo Markets Close in:



Currencies
Europe Markets
London Markets


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Ionis Pharmaceuticals Inc.

                  NASDAQ: IONS
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Ionis Pharmaceuticals Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 5:29 p.m.


IONS

/quotes/zigman/63581627/composite


$
56.75




Change

+0.36
+0.64%

Volume
Volume 17,495
Quotes are delayed by 20 min








/quotes/zigman/63581627/composite
Previous close

$
			55.86
		


$
				56.39
			
Change

+0.53
+0.95%





Day low
Day high
$55.36
$57.77










52 week low
52 week high

            $24.58
        

            $57.77
        


















Insider Activity


Individual




Elizabeth L. Hougen



Ms. Elizabeth L. Hougen is Chief Financial Officer & Senior VP-Finance at Ionis Pharmaceuticals, Inc. Ms. Hougen was previously employed as Chief Financial Officer & Executive Director by Molecular Biosystems, Inc. She received her undergraduate degree from Franklin & Marshall College and an MBA from the University of San Diego.



Transactions


Date
Shares
Transaction
Value





07/01/2017
104


 



4,228


01/17/2017
539


 
Disposition at $46.29 per share.


24,951


01/17/2017
733


 
Disposition at $46.29 per share.


33,931


01/17/2017
256


 
Disposition at $46.29 per share.


11,851


01/17/2017
122


 
Disposition at $46.29 per share.


5,648


01/17/2017
623


 
Disposition at $46.29 per share.


28,839


01/15/2017
1,594


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
1,380


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
653


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2017
312


 
Derivative/Non-derivative trans. at $0 per share.


0


01/01/2017
199


 



4,131


12/05/2016
2,500


 
Disposition at $46.05 per share.


115,125


12/05/2016
2,500


 
Derivative/Non-derivative trans. at $11.27 per share.


28,175


11/14/2016
2,500


 
Disposition at $47.5 per share.


118,750


11/14/2016
2,500


 
Derivative/Non-derivative trans. at $11.27 per share.


28,175


11/11/2016
2,500


 
Disposition at $41 per share.


102,500


11/11/2016
2,500


 
Derivative/Non-derivative trans. at $11.27 per share.


28,175


11/09/2016
2,500


 
Disposition at $38.49 per share.


96,225


11/09/2016
2,500


 
Derivative/Non-derivative trans. at $11.27 per share.


28,175


07/01/2016
217


 



4,504


01/19/2016
747


 
Disposition at $41.47 per share.


30,979


01/19/2016
261


 
Disposition at $41.46 per share.


10,822


01/19/2016
125


 
Disposition at $41.46 per share.


5,183


01/19/2016
216


 
Disposition at $41.47 per share.


8,958


01/19/2016
550


 
Disposition at $41.47 per share.


22,809


01/15/2016
1,380


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
654


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
312


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2016
541


 
Derivative/Non-derivative trans. at $0 per share.


0


01/01/2016
41


 



1,956


07/01/2015
40


 



1,943


03/19/2015
10,000


 
Disposition at $73.33 per share.


733,300


03/19/2015
10,000


 
Derivative/Non-derivative trans. at $11.27 per share.


112,700


03/05/2015
7,437


 
Disposition at $71.32 per share.


530,407


03/05/2015
7,437


 
Derivative/Non-derivative trans. at $7.25 per share.


53,918


03/05/2015
8,000


 
Disposition at $71.67 per share.


573,360


03/05/2015
8,000


 
Derivative/Non-derivative trans. at $7.25 per share.


58,000


03/05/2015
12,657


 
Disposition at $71.67 per share.


907,128


03/05/2015
12,657


 
Derivative/Non-derivative trans. at $14.47 per share.


183,146


01/16/2015
714


 
Disposition at $67.96 per share.


48,524


01/16/2015
250


 
Disposition at $67.96 per share.


16,990


01/16/2015
120


 
Disposition at $67.96 per share.


8,156


01/16/2015
207


 
Disposition at $67.96 per share.


14,068


01/15/2015
1,875


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
654


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
313


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2015
541


 
Derivative/Non-derivative trans. at $0 per share.


0


01/01/2015
63


 



1,893


01/16/2014
120


 
Disposition at $47.08 per share.


5,650


01/16/2014
207


 
Disposition at $47.08 per share.


9,746


01/16/2014
250


 
Disposition at $47.08 per share.


11,770


01/15/2014
313


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2014
542


 
Derivative/Non-derivative trans. at $0 per share.


0


01/15/2014
654


 
Derivative/Non-derivative trans. at $0 per share.


0


04/24/2013
10,417


 
Disposition at $22.38 per share.


233,133


04/24/2013
10,417


 
Derivative/Non-derivative trans. at $15.38 per share.


160,213


04/22/2013
2,000


 
Disposition at $21.43 per share.


42,860


04/22/2013
2,000


 
Derivative/Non-derivative trans. at $15.38 per share.


30,760


04/22/2013
3,000


 
Disposition at $21.41 per share.


64,230


04/22/2013
3,000


 
Derivative/Non-derivative trans. at $15.38 per share.


46,140


04/22/2013
2,813


 
Disposition at $21.4 per share.


60,199


04/22/2013
2,813


 
Derivative/Non-derivative trans. at $15.38 per share.


43,263


04/22/2013
9,843


 
Disposition at $21.49 per share.


211,527


04/22/2013
9,843


 
Derivative/Non-derivative trans. at $14.47 per share.


142,428


03/20/2013
4,792


 
Disposition at $18.13 per share.


86,879


03/20/2013
4,792


 
Derivative/Non-derivative trans. at $11.12 per share.


53,287


03/20/2013
9,584


 
Disposition at $18.13 per share.


173,758


03/20/2013
9,584


 
Derivative/Non-derivative trans. at $11.12 per share.


106,574


03/05/2013
5,040


 
Disposition at $16.86 per share.


84,975


03/05/2013
5,040


 
Derivative/Non-derivative trans. at $6.81 per share.


34,322


01/16/2013
242


 
Disposition at $14 per share.


3,388


01/15/2013
542


 
Derivative/Non-derivative trans. at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Dr. Stanley T. Crooke 
Chairman, President & Chief Executive Officer




Ms. B. Lynne Parshall 
Chief Operating Officer & Director




Ms. Elizabeth L. Hougen 
Chief Financial Officer & Senior VP-Finance




Ms. Paula  Soteropoulos 
President & CEO-Akcea Therapeutics




Dr. C. Frank Bennett 
Senior Vice President-Antisense Research




Dr. Brett P. Monia 
Senior VP-Drug Discovery & Corporate Development




Dr. Rosanne  Crooke 
Executive Director-Cardiovascular Diseases




Dr. Eugene  Schneider 
Vice President-Clinical Development




Dr. Richard S. Geary 
Senior Vice President-Development




Ms. Sarah  Boyce 
Chief Business Officer




Dr. D. Wade Walke 
VP-Corporate Communications & Investor Relations




Mr. Patrick R. O'Neil 
Secretary, Senior VP-Legal & General Counsel




Mr. Frederick T. Muto 
Independent Director




Dr. Joseph  Loscalzo 
Independent Director




Mr. Breaux B. Castleman 
Independent Director




Mr. Joseph H. Wender 
Independent Director




Mr. Joseph R. Klein 
Independent Director




Dr. Spencer R. Berthelsen 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




12:51 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Open





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
11:04pThe dark side of cruises
5:37pAt least 9 dead after overheated tractor-trailer found outside Texas Walmart
5:01p‘Full transparency’ doesn’t mean what Scaramucci apparently thinks it means
5:00pStocks brace for volatility in earnings deluge; Fed meeting looms
4:53pIf you suddenly quit your job like Sean Spicer, here’s what you should do next
4:52pNever (ever) say these things to a co-worker
4:51pMy uncle with dementia needs long-term care — should I refinance his house?
4:49pThis is the deadliest time of your life to put on weight
4:45pWhy house prices in gay neighborhoods are soaring
4:45pNearly 40% of adults don’t have life insurance — these startups are trying to change that
4:44pMarie Kondo says this one thing could be holding you back from falling in love
4:44pThis luxury credit card is only for truly big spenders
4:43pBanks have raised credit-card interest rates — but not savings account rates
12:13aHeavy showers swamp New Orleans street with rainwater
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































